Smoking Cessation Strategies After Acute Coronary Syndrome

Overview

Journal J Clin Med

Specialty General Medicine

Date 2025 Feb 26

PMID 40004917

Authors

Anum Nazir

Smrthi Shetty Ujjar

Moncef Oualid Seddiki

Mala Jheinga

Lampson Fan

Affiliations

Soon will be listed here.

Abstract

Smoking is one of the strongest modifiable risk factors for coronary artery disease. It is the cause of approximately 10-30% of deaths due to cardiovascular disease around the world. There is a 50% reduction in the risk of myocardial infarction by one year for people who successfully quit smoking. Considering the risk associated with smoking and the benefits of smoking cessation, it is important to identify and implement effective smoking cessation strategies. There are pharmacological as well as non-pharmacological interventions to assist in smoking cessation. Pharmacological therapies including nicotine replacement therapy; bupropion and varenicline have generally been studied more in patients with cardiovascular disease than the non-pharmacological interventions. Non-pharmacological strategies for smoking cessation include behavioural interventions such as counselling sessions and cognitive behavioural therapy. Studies and randomised controlled trials have demonstrated the safety of most of the pharmacological interventions. Nonetheless, the success rates are variable for the different pharmacological options. Data suggest that greater success can be achieved in smoking cessation with a combination of pharmacological and non-pharmacological treatment. However, more studies are needed to explore the best therapeutic options to improve the success of smoking cessation.

References

Matkin W, Ordonez-Mena J, Hartmann-Boyce J . Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2019; 5:CD002850. PMC: 6496404. DOI: 10.1002/14651858.CD002850.pub4. View

Chehab O, Dakik H . Interventions for smoking cessation in patients admitted with Acute Coronary Syndrome: a review. Postgrad Med J. 2017; 94(1108):116-120. DOI: 10.1136/postgradmedj-2017-135040. View

Tonstad S, Davies S, Flammer M, Russ C, Hughes J . Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010; 33(4):289-301. DOI: 10.2165/11319180-000000000-00000. View

Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N . Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022; 4:CD013696. PMC: 9009295. DOI: 10.1002/14651858.CD013696.pub2. View

Siskind D, Wu B, Wong T, Firth J, Kisely S . Pharmacological interventions for smoking cessation among people with schizophrenia spectrum disorders: a systematic review, meta-analysis, and network meta-analysis. Lancet Psychiatry. 2020; 7(9):762-774. DOI: 10.1016/S2215-0366(20)30261-3. View

Hughes J . Motivating and helping smokers to stop smoking. J Gen Intern Med. 2003; 18(12):1053-7. PMC: 1494968. DOI: 10.1111/j.1525-1497.2003.20640.x. View

Ware J, Vetrovec G, Miller A, Van Tosh A, Gaffney M, Yunis C . Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials. Am J Ther. 2013; 20(3):235-46. DOI: 10.1097/MJT.0b013e31828d455b. View

Rigotti N, Thorndike A, Regan S, McKool K, Pasternak R, Chang Y . Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. 2006; 119(12):1080-7. DOI: 10.1016/j.amjmed.2006.04.024. View

Niaura R . Nonpharmacologic therapy for smoking cessation: characteristics and efficacy of current approaches. Am J Med. 2008; 121(4 Suppl 1):S11-9. DOI: 10.1016/j.amjmed.2008.01.021. View

10.

Siddiqi T, Rashid A, Siddiqi A, Anwer A, Usman M, Sakhi H . Association of Electronic Cigarette Exposure on Cardiovascular Health: A Systematic Review and Meta-Analysis. Curr Probl Cardiol. 2023; 48(9):101748. DOI: 10.1016/j.cpcardiol.2023.101748. View

11.

Jeong S, Newcombe D, Sheridan J, Tingle M . Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal. 2014; 7(6):475-82. DOI: 10.1002/dta.1707. View

12.

Giulietti F, Filipponi A, Rosettani G, Giordano P, Iacoacci C, Spannella F . Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev. 2020; 27(5):349-362. PMC: 7309212. DOI: 10.1007/s40292-020-00396-9. View

13.

Brewer J, Mallik S, Babuscio T, Nich C, Johnson H, DeLeone C . Mindfulness training for smoking cessation: results from a randomized controlled trial. Drug Alcohol Depend. 2011; 119(1-2):72-80. PMC: 3191261. DOI: 10.1016/j.drugalcdep.2011.05.027. View

14.

Cahill K, Stevens S, Perera R, Lancaster T . Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; (5):CD009329. PMC: 8406789. DOI: 10.1002/14651858.CD009329.pub2. View

15.

Cahill K, Lindson-Hawley N, Thomas K, Fanshawe T, Lancaster T . Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016; (5):CD006103. PMC: 6464943. DOI: 10.1002/14651858.CD006103.pub7. View

16.

Doll R, Peto R, Boreham J, Sutherland I . Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004; 328(7455):1519. PMC: 437139. DOI: 10.1136/bmj.38142.554479.AE. View

17.

Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T . Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med. 2011; 171(12):1055-60. DOI: 10.1001/archinternmed.2011.72. View

18.

Vogeler T, McClain C, Evoy K . Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016; 42(2):129-39. DOI: 10.3109/00952990.2015.1117480. View

19.

Hajek P, Taylor T, Mills P . Brief intervention during hospital admission to help patients to give up smoking after myocardial infarction and bypass surgery: randomised controlled trial. BMJ. 2002; 324(7329):87-9. PMC: 64504. DOI: 10.1136/bmj.324.7329.87. View

20.

Stead L, Lancaster T . Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2002; (3):CD001007. DOI: 10.1002/14651858.CD001007. View